All In Biotech

Drug Trial Radar · NCT02324452

Safety, Feasibility and Cost-effectiveness of Genotype-directed Individualized Dosing of Fluoropyrimidines

Last checked: Nov 19, 2026Latest source record: May 11, 2018 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

1,103

Actual

Start

Mar 2015

Primary completion

Jan 2018

Study completion Mar 2018

Sponsor

Lead sponsor
The Netherlands Cancer InstituteAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Dec 24, 2014

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable
Allocation
Non randomized
Model
Single group
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

In this study it will be determined whether the rate of severe toxicity associated with fluoropyrimidine treatment (capecitabine or 5-fluorouracil) can be significantly diminished by individualized dosing of fluoropyrimidines based on upfront genotypic assessment of dihydropyrimidine dehydrogenase (DPD) deficiency. In addition to the genotyping, the DPD phenotype of all patients will be determined by measuring the baseline dihydrouracil/uracil (DHU/U) ratio, in order to investigate whether phenotype-guided treatment can further improve patient safety. In a subgroup of patients, other phenotyping methods will be tested: measuring the plasma levels of uracil after a uracil test dose and a uracil breath test after a dose of \[2-13C\] -labeled uracil. To validate these tests, these phenotyping results will be compared with the results of a DPD activity assay (which measures DPD enzyme activity in peripheral blood mononuclear cells), which is considered the gold standard in measuring DPD phenotype.

Conditions

  • Neoplasms

Interventions

  • Fluoropyrimidine (capecitabine or 5-fluorouracil)Drug

    Patient that are a heterozygous carrier of a DPYD variant will receive a reduced dosage of capecitabine or 5-fluorouracil (25-50% reduction, depending on which SNP is identified). The dose will be titrated in subsequent cycles, to achieve maximal safe exposure. Patients that are wild type (not carrying any of the for DPYD variants) will receive a normal (full) dose.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Safety: incidence of severe treatment-related toxicity (CTC grade 3 to 5)Time frame: patients will be followed during fluoropyrimidine treatment, expected average of 1 year

Locations

17 sites in 1 country. Site status is shown where the registry gives one.

  • Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital

    Amsterdam, Netherlands

  • Wilhelmina Hospital Assen

    Assen, Netherlands

  • Amphia Hospital

    Breda, Netherlands

  • Reinier de Graaf Hospital

    Delft, Netherlands

  • Deventer Hospital

    Deventer, Netherlands

  • Hospital Gelderse Vallei

    Ede, Netherlands

  • Catharina Hospital

    Eindhoven, Netherlands

  • Leiden University Medical Center

    Leiden, Netherlands

  • Maastricht University Medical Center

    Maastricht, Netherlands

  • Canisius-Wilhelmina Hospital

    Nijmegen, Netherlands

  • Laurentius Hospital

    Roermond, Netherlands

  • Bravis Hospital

    Roosendaal, Netherlands

  • Erasmus MC

    Rotterdam, Netherlands

  • Franciscus Gasthuis & Vlietland

    Rotterdam, Netherlands

  • Haga Hospital

    The Hague, Netherlands

  • Medical Center Haaglanden

    The Hague, Netherlands

  • University Medical Center Utrecht

    Utrecht, Netherlands

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.